Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology
ABSTRACT Familial diffuse Lewy body disease (DLBD) is rare and not yet associated with a defect in the synuclein gene. In the differential diagnosis of the parkinsonian syndromes, defects in vertical gaze tend to be identified with progressive supranuclear palsy. False-positive diagnosis of progressive supranuclear palsy can occur, and defects in vertical gaze have been reported in DLBD, although so far a pure vertical gaze palsy associated with pathological abnormalities in the substrate for vertical gaze has not been described.
To report the clinical and pathological findings in 2 siblings with DLBD, and to relate the distribution of the pathological abnormalities in the brainstem to centers for vertical gaze.
For several years, 2 Irish siblings experienced a progressive parkinsonism-dementia complex associated in one with a defect in vertical gaze and in both with visual hallucinations.
In both patients, results of pathological examination revealed (1) Lewy bodies positive for ubiquitin and alpha-synuclein together with cell loss and gliosis in the substantia nigra, locus ceruleus, and neocortex; and (2) similar findings in the rostral interstitial nucleus of the medial longitudinal fasciculus, the posterior commissure, and the interstitial nucleus of Cajal (substrates for vertical gaze).
Familial DLBD (not shown to be genetically as distinct from environmentally transmitted) has been shown to exist in an Irish family. Caution should be enjoined in the interpretation of defects in vertical gaze in the differential diagnosis of the parkinsonian syndromes.
Article: Malattia a corpi di Lewy[Show abstract] [Hide abstract]
ABSTRACT: La malattia a corpi di Lewy fu descritta per la prima volta nel 1984 come una demenza neurodegenerativa associata, sul piano istologico, a dei corpi di Lewy osservati principalmente nella sostanza nera della via nigrostriatale, come nella malattia di Parkinson, ma anche nelle regioni corticali. Le alterazioni neuropsicologiche che si possono osservare allo stadio del disturbo cognitivo leggero, ben prima dello stadio demenziale, sono caratterizzate da una sindrome disesecutiva con una ripercussione sulle capacità di memorizzazione e da una riduzione delle prestazioni spaziali. Sono classicamente associati dei disturbi del sonno paradosso, delle allucinazioni visive precoci, una sindrome parkinsoniana, delle fluttuazioni motorie e cognitive, una disautonomia e un’ipersensibilità ai neurolettici. Gli inibitori dell’acetilcolina-esterasi possono mostrare una certa efficacia sui disturbi cognitivi, mentre la L-dopa può fornire dei benefici riguardo alla sindrome parkinsoniana, se la sindrome allucinatoria e la disautonomia non ne impediscono l’utilizzo. Sono, d’altra parte, fortemente consigliate delle misure non farmacologiche, in particolare la gestione dei disturbi del comportamento e la fisioterapia.11/2014; 14(4). DOI:10.1016/S1634-7072(14)68870-X
[Show abstract] [Hide abstract]
ABSTRACT: A growing number of PSEN1 mutations have been associated with dementia with Lewy bodies and familial Alzheimer's disease with concomitant α-synuclein pathology. The objective of this study was to determine if PSEN1 plays a direct role in the development of α-synuclein pathology in these diseases. Using mass spectrometry, immunoelectron microscopy and fluorescence lifetime image microscopy based on Forster resonance energy transfer (FLIM-FRET) we identified α-synuclein as a novel interactor of PSEN1 in wild-type mouse brain tissue. The interaction of α-synuclein with PSEN1 was detected in post-mortem brain tissue from cognitively normal cases and was significantly increased in tissue from cases with dementia with Lewy bodies and familial Alzheimer's disease associated with known PSEN1 mutations. We confirmed an increased interaction of PSEN1 and α-synuclein in cell lines expressing well characterized familial Alzheimer's disease PSEN1 mutations, L166P and delta exon 9, and demonstrated that PSEN1 mutations associate with increased membrane association and accumulation of α-synuclein. Our data provides evidence of a molecular interaction of PSEN1 and α-synuclein that may explain the clinical and pathophysiological overlap seen in synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and some forms of Alzheimer's disease.Brain 05/2014; 137. DOI:10.1093/brain/awu119 · 10.23 Impact Factor
Aging Health 06/2006; 2(3):461-472. DOI:10.2217/1745509X.2.3.461